BTC Capital Management Trims Amgen Stake by 38%

Institutional investor reduces holdings in biotech giant during Q4 2025

Apr. 1, 2026 at 7:40am

Got story updates? Submit your updates here. ›

BTC Capital Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 38.1% during the fourth quarter of 2025, according to the company's latest 13F filing with the SEC. The institutional investor now owns 6,812 shares of the medical research company's stock, down from 10,008 shares held previously.

Why it matters

Amgen is one of the largest and most influential biotech companies, so changes to major institutional investors' holdings can signal broader market trends and investor sentiment around the stock. This reduction in BTC Capital's Amgen stake may indicate a shift in the firm's outlook on the company or the broader biotech sector.

The details

According to the 13F filing, BTC Capital Management sold 4,196 shares of Amgen stock during the fourth quarter. The firm's remaining 6,812 shares were valued at $2,228,000 as of the end of the quarter. Amgen's stock price has fluctuated in recent months, trading between $261.43 and $391.29 over the past 52 weeks.

  • BTC Capital Management filed its 13F report for the fourth quarter of 2025 on April 1, 2026.
  • The firm reduced its Amgen holdings during the three-month period ending December 31, 2025.

The players

BTC Capital Management Inc.

An institutional investment firm that manages a portfolio of stocks, including shares of biotech giant Amgen.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

What they’re saying

“Amgen has historically been a core holding in many institutional portfolios, so changes to major investors' positions can be noteworthy.”

— Analyst

What’s next

Investors and analysts will likely monitor Amgen's stock performance and any further changes to the company's institutional ownership in the coming quarters.

The takeaway

This reduction in BTC Capital's Amgen stake could signal a shift in investor sentiment around the biotech sector, though the reasons behind the firm's portfolio adjustment remain unclear based on the limited information provided in the 13F filing.